Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

BACKGROUND: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) recurring/progressing on/after nonsteroi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast
Hlavní autoři: Steger, Guenther G., Egle, Daniel, Bartsch, Rupert, Pfeiler, Georg, Petru, Edgar, Greil, Richard, Helfgott, Ruth, Marth, Christian, Öhler, Leopold, Hubalek, Michael, Lang, Alois, Tinchon, Christoph, Haslbauer, Ferdinand, Redl, Andreas, Hock, Karin, Hennebelle, Mathias, Mraz, Bernhard, Gnant, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375626/
https://ncbi.nlm.nih.gov/pubmed/32062536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.01.035
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky